I think you are jumbling the arguments (social responsibility is not the angle I am suggesting here, rather, that is another topic involving the massive overproduction, overprescribing, and over-consumption of certain presc. meds). In this example, the risk aversion you refer to (cutting down of BP inhouse R&D)equates to a pooling of those resources (some of them anyway) into biotech for R&D purposes.
Market Data 
Markets 
AI
